Largest study to date of Boston Scientific's S-ICD 'leadless' defibrillator released

Mon, 10/08/2012 - 6:30pm
Mass Device

The largest study yet of Boston Scientific's S-ICD "leadless" defibrillator shows that its safety and performance match standard, transvenous devices.

Boston Scientific

A new study of the so-called "leadless" defibrillator made by Boston Scientific (NYSE:BSX) shows that the device matches the safety and performance of standard defibrillators, which use leads threaded through blood vessels to deliver shocks to the heart.

The S-ICD device, which Boston Scientific acquired when it bought Cameron Health earlier this year, won pre-market approval from the FDA this week. Instead of transvenous leads, the S-ICD uses leads that are implanted subcutaneously. The shock therapy is delivered through the sternum to the heart.

The Effortless real-world study showed a rate of inappropriate shocks for the S-ICD of nearly 7%, about ½ that of the 330-patient investigational device exemption trial behind the FDA approval. Nearly 90% of ventricular fibrillation episodes were converted with the S-ICD, versus 90.8% for the control arm of the trial, according to heartwire. Complications rates were low and also comparable, according to the website.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.